Inventor
FITZGERALD JONATHAN BASIL
US19 patents
⚠️ This page may combine multiple inventors who share the name “FITZGERALD JONATHAN BASIL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
IPSEN BIOPHARM LTD
10 patentsUS9717724B2Aug 1, 2017
Methods for treating pancreatic cancer using combination therapies
IPSEN BIOPHARM LTD14 citations91
US10980795B2Apr 20, 2021
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
IPSEN BIOPHARM LTD8 citations83
US10478428B2Nov 19, 2019
Combination therapy for cancer treatment
IPSEN BIOPHARM LTD11 citations82
US9895365B2Feb 20, 2018
Combination therapy for cancer treatment
IPSEN BIOPHARM LTD10 citations82
US11369597B2Jun 28, 2022
Methods for treating pancreatic cancer using combination therapies
IPSEN BIOPHARM LTD4 citations72
US11844795B2Dec 19, 2023
Combination therapy for cancer treatment
IPSEN BIOPHARM LTD2 citations71
US11318131B2May 3, 2022
Nanoliposomal irinotecan for use in treating small cell lung cancer
IPSEN BIOPHARM LTD3 citations70
US11344552B2May 31, 2022
Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
IPSEN BIOPHARM LTD4 citations69
US11071726B2Jul 27, 2021
Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
IPSEN BIOPHARM LTD6 citations67
US12364691B2Jul 22, 2025
Methods for treating pancreatic cancer using combination therapies
IPSEN BIOPHARM LTD0 citations61
MERRIMACK PHARMACEUTICALS INC
7 patentsUS9492442B2Nov 15, 2016
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
MERRIMACK PHARMACEUTICALS INC19 citations91
US9452162B2Sep 27, 2016
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
MERRIMACK PHARMACEUTICALS INC12 citations91
US9364473B2Jun 14, 2016
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
MERRIMACK PHARMACEUTICALS INC12 citations91
US9339497B2May 17, 2016
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
MERRIMACK PHARMACEUTICALS INC17 citations91
US9556274B2Jan 31, 2017
Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodies
MERRIMACK PHARMACEUTICALS INC2 citations71
US9527914B2Dec 27, 2016
Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
MERRIMACK PHARMACEUTICALS INC1 citations61
US9938346B2Apr 10, 2018
Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
MERRIMACK PHARMACEUTICALS INC0 citations50